



Top 46-50

09 June 2011 | News





Synchron Research Services

CMD
Dr Shivprakash

46

Business: Provides clinical research services from phase I to phase IV


Start-up Year: 1998

Address: The Chambers, 3rd Floor, Sarkhej-Gandhinagar Highway, Bodakdev, Ahmedabad - 380 054

Tel: +91-79-26853419, 26840427
Fax: +91-79-26853415
Website: www.synchronresearch.com

Revenue: ₹63 crore*

Synchron Research Services reported an estimated revenue of ₹63 crore in 2010-11 as compared to previous year's estimated revenue of ₹57 crore. It is a leading CRO in India, which provides a broad range of clinical research services from phase I to phase IV, including bioavailability, bioequivalence, pharmacokinetic, pharmacodynamic studies, dermato-pharmacokinetics, bioanalysis, statistical analysis, data management and pharmacovigilance. It has a 30-bed facility in Bangkok called Bio-Innova Synchron Research to serve the Asia Pacific region, which was formed by a joint venture between Bio-innova and Synchron Research. Synchron also acquired Innovance, an Ahmedabad-based start-up CRO having a clinical research facility. The new clinical facility is spread across 18,000 sq ft on a single floor, with three different volunteer housing areas. The new 80 beds will be an addition to the already existing 90 beds in the existing facility, thus totaling to 200 beds across Asia.



JK Agri Genetics

President
Mr P S Dravid

47

Business: Involved in R&D and marketing of agri biotech products


Start-up Year: 1989

JK Agri Genetics Limited (JKAL), an erstwhile division of JK Tyre & Industries, clocked a total turnover of ₹50.66 crore in 2010-11 when compared with the last year's revenue of ₹32.50 crore. The company is focused on R&D, production, processing and marketing of hybrid seeds of sorghum, pearl millet, maize, cotton, rice, sunflower, tomato, okra and hot pepper. There are many hybrids marketed by the company, including fast-moving hybrids such as JK 99, JK Durga, JK 666, JK Indra, JK Varun (555), JK Chamundi. The firm has a team of 15 committed scientists working on different areas of biotechnology. JKAL is planning to diversify its research into medicinal and aromatic plants in core activities such as cultivation, contract farming, varietal development, quality extract production and chemical & DNA finger

Address: 1-20-177, 4th Floor, Varun Towers, Begumpet, Hyderabad-500016

Tel: +91-40-66316858
Fax: +91-40-27764943
Website: www.jkseeds.net

Revenue: ₹50.66 crore*



Wockhardt

Chairman
Mr Habil F Khorakiwala

48

Business: Pharmaceutical and biotechnology business


Start-up Year: 1960

Address: Wockhardt Towers, Bandra Kurala Complex, Bandra (East), Mumbai-400051

Tel: +91-22-26596258
Fax: +91-22-26596801
Website: www.wockhardt.in

Revenue: ₹50 crore*

Wockhardt, the first company in Asia to launch its recombinant human insulin product, Wosulin, in 2003, recorded an estimated biotech revenue of ₹ 50 crore for 2010-11. In Feb 2011, Wockhardt entered into a strategic global alliance with Sheffield Bio-Science, a Kerry Group Business from the US, under which the latter will have exclusive sales and distribution rights to supply the recombinant insulin to the cell culture markets worldwide. Wockhardt announced in 2009 that it was experiencing liquidity crisis and was reportedly facing a debt burden of more than ₹3,000 crore. Following this, there were talks that the company would sell its biotech division. Companies like Pfizer and Sanofi Aventis were on the run to acquire this unit, and its valuations reached a whopping ₹250 crore. Presently, the firm's R&D is based in Aurangabad & Mumbai; Negma Laboratories in France; Morton Grove Pharmaceuticals in Illinois, US; Pinewood, Ireland and in UK.



Max Neeman International

CEO
Dr Ajoy Kumar

49

Business: Clinical research services


Start-up Year: 2001

Address: Max House, 1 Dr Jha Marg, Okhla III, New Delhi-110020

Tel: +91-11-40772100
Fax: +91-11-28322846
Website: www.neeman-medical.com

Revenue: ₹48.4 crore

Max Neeman International, a subsidiary of the Max India Group, registered a growth of 21 percent from ₹40 crore in FY 2009-10 to ₹48.4 crore in FY 2010-11. The firm offers a full range of clinical research services with focus on phase I-IV trials for drugs, devices, nutraceuticals and cosmetics in compliance with ICH GCP standards. It is based out of six regional offices and has 175 active sites in 22 cities, with access to over 900 GCP trained investigators. Max Neeman is a ISO 9001:2008 and ISO 27001 certified organization. The number of trials of the firms reached 200 and the CRO has a total client base of 65 companies across the globe. Max Neeman has consistently maintained a patient retention rate of above 98 percent across multiple therapeutic areas for all its studies. Max Neeman successfully completed four FDA audits for the highest enrollment globally and has been successfully audited around 40 times by the sponsor companies.



Clinigene International

COO
Dr Abhijit Barve

Clinigene International, the full service clinical research arm of biotech major, Biocon, registered a turnover of ₹43 crore in FY 2010-11 as compared to ₹39 crore in the FY 2009-10. In the year 2010, studies conducted by Clinigene were successfully audited by the USFDA and EMA without Form 483 or critical findings. In addition to the standard service platforms, the company has identified several more specialized areas, such as patient-based early studies, complex BA/BE studies and bio-analytical services, where customers are now

50	**Business:** Clinical research
	Start-up Year: 1996
Address: Clinigene House, Tower 1, Semicon Park, Electronic City, Phase II, Bangalore-560100	
Tel: +91-80-28082808 **Fax:** +91-80-28083150 **Website:** www.clinigeneintl.com	
Revenue: ☒43 crore	